Printer Friendly

A.L. LABORATORIES ANNOUNCES FDA APPROVAL FOR LOPERAMIDE CAPLETS

 FORT LEE, N.J., Dec. 7 /PRNewswire/ -- A.L. Laboratories, Inc. (NYSE: BMD), today announced that its U.S. Pharmaceuticals group has received approval from the Food and Drug Administration (FDA) to manufacture and market Loperamide Hydrochloride Caplets, 2 mg.
 Loperamide Caplets, an anti-diarrheal, will be competitive with the branded, over-the-counter product, Imodium A-D. The solid-dose Loperamide market is presently in excess of $75 million. Loperamide Caplets will complement the Company's Loperamide Hydro-chloride Oral Solution, which was approved in September 1992. The Company expects to begin marketing Loperamide Caplets in the first quarter of 1994.
 The approval for Loperamide Caplets was received by the Company's Able Laboratories subsidiary and represents the third new product approval for Able Labs in the last month. Approvals for Miconazole Vaginal Suppositories 100 mg and 200 mg strengths were recently announced.
 A.L. Laboratories is a multinational manufacturer and marketer of specialized and value-added, branded pharmaceuticals and animal health micronutrients, with plant sites in Illinois, Maryland, New Jersey, New York, North Carolina, Washington State, Denmark and Indonesia.
 -0- 12/7/93
 /CONTACT: Iris Daniels, Investor Relations Manager of A.L. Laboratories, 201-947-7774/
 (BMD)


CO: A.L. Laboratories, Inc. ST: New Jersey IN: MTC SU:

TW -- NY057 -- 1295 12/07/93 12:53 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 7, 1993
Words:208
Previous Article:THE BANK OF NEW YORK TO ACQUIRE FACTORING BUSINESS OF BANK OF BOSTON
Next Article:RHONE-POULENC RORER TO HOST BUFFET BREAKFAST DEC. 17 TO INTRODUCE NEW PRESIDENT AND CHIEF OPERATING OFFICER
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters